Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

http://scihub22266oqcxt.onion/ 3962310!ä!3962310 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Wien+Klin+Wochenschr 1986 ; 98 (2): 49-53 Nephropedia Template TP {{tp|p=3962310|t=1986. Kaliumsparende Wirkung von Triamteren in einem Dreifachkombinationspraparat zur Therapie der Hypertonie |pdf=|usr=}}{{3962310}} gab.com Text Kaliumsparende Wirkung von Triamteren in einem Dreifachkombinationspraparat zur Therapie der Hypertonie JO: Wien Klin Wochenschr http://www.kidney.de/pget.php?&tw=1&pmid=3962310 #FOAvip A new fixed-dose combination drug, Minotensin (1 film-coated tablet contains 120 mg bupranolol, 2.5 mg bendroflumethiazide and 25 mg triamterene) was tested in a long-term study. 20 patients with mild to moderate primary hypertension were treated for 6 months. Items of investigation were: influence on low range serum potassium, influence on serum magnesium concentration, blood pressure lowering effect, tolerance and side effects. Initial dosage of 1 tablet b.i.d. could be reduced to 1 tablet in the morning in 4 patients. The mean serum potassium concentration rose from 3.79 +/- 0.3 mmol/l to 4.15 +/- 0.55 mmol/l (p less than 0.01) after 4 weeks, and to 4.26 +/- 0.37 mmol/l (p less than 0.001) after 6 months of treatment, all single values remaining within normal limits. The serum magnesium concentration rose to a small, insignificant extent. Systolic and diastolic blood pressure were lowered highly significantly from 177 +/- 12/103 +/- 7 mm Hg by 19/11 mm Hg. The mean values were within normal limits (less than 160/95 mm Hg) after treatment. Heart rate fell simultaneously by 11 beats per minute, on average (p less than 0.01). Atrioventricular conduction time was slightly prolonged in 2 cases. Serum levels of sodium, BUN and creatinine rose slightly, but remained within the normal range during treatment. Uric acid and lipids were not influenced significantly. 1 patient complained of transient gastrointestinal discomfort. Generally the drug was tolerated very well. Twit Text FOAVip Kaliumsparende Wirkung von Triamteren in einem Dreifachkombinationspraparat zur Therapie der Hypertonie ????Wien Klin Wochenschr http://www.kidney.de/pget.php?&tw=1&pmid=3962310 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=3962310 #FOAvip English Wikipedia <ref>{{Cite pmid|3962310}}</ref> Kaliumsparende Wirkung von Triamteren in einem Dreifachkombinationspraparat zur Therapie der Hypertonie #MMPMID3962310 Nagler J; Dittrich H Wien Klin Wochenschr 1986[Jan]; 98 (2): 49-53 PMID3962310show ga A new fixed-dose combination drug, Minotensin (1 film-coated tablet contains 120 mg bupranolol, 2.5 mg bendroflumethiazide and 25 mg triamterene) was tested in a long-term study. 20 patients with mild to moderate primary hypertension were treated for 6 months. Items of investigation were: influence on low range serum potassium, influence on serum magnesium concentration, blood pressure lowering effect, tolerance and side effects. Initial dosage of 1 tablet b.i.d. could be reduced to 1 tablet in the morning in 4 patients. The mean serum potassium concentration rose from 3.79 +/- 0.3 mmol/l to 4.15 +/- 0.55 mmol/l (p less than 0.01) after 4 weeks, and to 4.26 +/- 0.37 mmol/l (p less than 0.001) after 6 months of treatment, all single values remaining within normal limits. The serum magnesium concentration rose to a small, insignificant extent. Systolic and diastolic blood pressure were lowered highly significantly from 177 +/- 12/103 +/- 7 mm Hg by 19/11 mm Hg. The mean values were within normal limits (less than 160/95 mm Hg) after treatment. Heart rate fell simultaneously by 11 beats per minute, on average (p less than 0.01). Atrioventricular conduction time was slightly prolonged in 2 cases. Serum levels of sodium, BUN and creatinine rose slightly, but remained within the normal range during treatment. Uric acid and lipids were not influenced significantly. 1 patient complained of transient gastrointestinal discomfort. Generally the drug was tolerated very well. |Bendroflumethiazide/*therapeutic use[MESH] |Blood Pressure/drug effects[MESH] |Bupranolol/*therapeutic use[MESH] |Drug Combinations/therapeutic use[MESH] |Female[MESH] |Heart Rate/drug effects[MESH] |Humans[MESH] |Hypertension/*drug therapy[MESH] |Male[MESH] |Middle Aged[MESH] |Potassium/blood[MESH] |Propanolamines/*therapeutic use[MESH]Kaliumsparende Wirkung von Triamteren in einem Dreifachkombinationspra(epmc).pdf DeepDyve Pubget Overpricing